logo
logo

RDMD Secures $14 Million in Series A Financing and Announces Partnership with UCB in Rare Neurodegenerative Disease

Apr 16, 2020•over 5 years ago

Amount Raised

$14 Million

Round Type

series a

San Francisco

Description

RDMD, a healthcare technology company dedicated to accelerating drug research for patients with rare diseases, today announced that it has raised $14 million in Series A financing. RDMD has developed an FDA-ready technology platform that generates deep clinical evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to participate in research from home. In conjunction with the financing, RDMD has also announced progress to date in these efforts.

Company Information

Company

Rdmd

Location

San Francisco, California, United States

About

RDMD is a healthcare technology company dedicated to accelerating treatments for patients with rare diseases. RDMD has developed a technology platform that generates FDA-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in drug research online and benefit from their own medical data. RDMD was founded by co-founder and CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, Spark Capital, Maveron Capital, Village Global, Garuda Ventures and a number of angel investors. For more information, visit www.rdmd.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech